Pulmonary subvalvular stenosis

Summary

Pulmonary subvalvular stenosis (MONDO:0006935) is a disease. A subtype of pulmonary valve stenosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pulmonary subvalvular stenosis
Mondo ID	MONDO:0006935
EFO	EFO:1001137
MeSH	D011662
DOID	DOID:8861
ICD-10-CM	Q24.3
NCIT	C34961
SNOMED CT	204370002
UMLS	C0034084
MedGen	11030
Is cancer (heuristic)	no

Also known as: congenital infundibular stenosis · infundibular pulmonic stenosis, congenital · pulmonary infundibular stenosis · subvalvular pulmonic stenosis

Disease family

This is a subtype of pulmonary valve stenosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › heart valve disorder › pulmonary valve disorder › pulmonary valve stenosis › pulmonary subvalvular stenosis

Related subtypes (1): Hordnes Engebretsen Knudtson syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.